Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age ≥ 18 years~2. willing to have bilateral femoral perineural catheters placed with a subsequent ropivacaine infusion and motor/sensory testing for 6 hours, requiring an overnight stay in the UCSD GCRC/CTRI to allow dissipation of local anesthetic infusion effects by the following morning~Exclusion Criteria:~1. current daily analgesic use~2. opioid use within the previous 4 weeks~3. any neuro-muscular deficit of either femoral nerves and/or quadriceps muscles~4. morbid obesity \[weight \> 35 kg/m2\]~5. pregnancy (as determined by a urine pregnancy test prior to any study interventions)~6. incarceration~We expect to recruit a maximum of 30 healthy volunteers; with a target goal of 24 for the analysis. Selection for inclusion will not be based on gender, race, or socioeconomic status. The study population of interest includes men and women of all races and socioeconomic status. There will be no participants from vulnerable populations, such as pregnant women, children, or prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4% (Type: EXPERIMENTAL): Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
- RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1% (Type: ACTIVE_COMPARATOR): Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).